Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov. 26, 2021 3:15 AM ETStarpharma Holdings Limited (SPHRY)By: Mamta Mayani, SA News Editor

Human Urinary System Kidneys with Bladder Anatomy

magicmine/iStock via Getty Images

  • Melbourne biotech Starpharma (OTCQX:SPHRY) announces positive interim results from the prostate cancer cohort in its ongoing Phase 2 trial of DEP cabazitaxel.
  • Starpharma's interim results in prostate cancer show that one or more efficacy signals were observed

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.